ATE500831T1 - Krebsbehandlungsverfahren - Google Patents

Krebsbehandlungsverfahren

Info

Publication number
ATE500831T1
ATE500831T1 AT06838636T AT06838636T ATE500831T1 AT E500831 T1 ATE500831 T1 AT E500831T1 AT 06838636 T AT06838636 T AT 06838636T AT 06838636 T AT06838636 T AT 06838636T AT E500831 T1 ATE500831 T1 AT E500831T1
Authority
AT
Austria
Prior art keywords
cancer treatment
treatment procedures
cancer
administration
relates
Prior art date
Application number
AT06838636T
Other languages
English (en)
Inventor
Arundathy Nirmalini Pandite
Bonnie F Whitehead
Peter T C Ho
Albert Benjamin Suttle
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE500831T1 publication Critical patent/ATE500831T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AT06838636T 2005-11-29 2006-11-29 Krebsbehandlungsverfahren ATE500831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74030805P 2005-11-29 2005-11-29
PCT/US2006/045777 WO2007064753A2 (en) 2005-11-29 2006-11-29 Cancer treatment method

Publications (1)

Publication Number Publication Date
ATE500831T1 true ATE500831T1 (de) 2011-03-15

Family

ID=37847172

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06838636T ATE500831T1 (de) 2005-11-29 2006-11-29 Krebsbehandlungsverfahren

Country Status (12)

Country Link
US (1) US20090005406A1 (de)
EP (2) EP1954281B1 (de)
JP (1) JP2009517397A (de)
AT (1) ATE500831T1 (de)
CY (1) CY1111390T1 (de)
DE (1) DE602006020611D1 (de)
DK (1) DK1954281T3 (de)
ES (1) ES2359517T3 (de)
HR (1) HRP20110244T1 (de)
PL (1) PL1954281T3 (de)
SI (1) SI1954281T1 (de)
WO (1) WO2007064753A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058307A1 (de) 2007-11-12 2009-05-13 Cellzome Ag Verfahren zur Identifizierung von mit JAK-Kinase wechselwirkenden Molekülen und zur JAK-Kinase-Reinigung
EP2490536A4 (de) * 2009-10-23 2013-04-17 Glaxo Wellcome Mfg Pte Ltd Zusammensetzung und verfahren
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
KR20140008303A (ko) 2010-10-27 2014-01-21 노파르티스 아게 안구 혈관 질환의 치료를 위한 투여 요법
EP2773204A4 (de) * 2011-10-31 2015-05-27 Glaxosmithkline Intellectual Property Ltd Pazopanib-formulierung
RU2014137190A (ru) * 2012-02-17 2016-04-10 Фармасайкликс, Инк. Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
CN103319410B (zh) * 2012-03-22 2016-04-06 天津药物研究院 一种吲唑化合物的合成方法
CN103232443B (zh) * 2013-02-01 2014-12-10 天津药物研究院 一种吲唑衍生物的晶型及其制备和用途
WO2015068175A2 (en) 2013-11-05 2015-05-14 Laurus Labs Private Limited An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CN110878089A (zh) * 2018-09-05 2020-03-13 江苏豪森药业集团有限公司 一种盐酸帕唑帕尼的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2311825T1 (sl) 2000-12-21 2016-02-29 Novartis Ag Pirimidinamini kot angiogenetski modulatorji
EP1353693B1 (de) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
AU2003276125B2 (en) 2002-06-17 2007-05-17 Smithkline Beecham Corporation Chemical process
EP1755394A4 (de) * 2004-04-16 2009-08-05 Smithkline Beecham Corp Krebsbehandlungsverfahren

Also Published As

Publication number Publication date
DE602006020611D1 (de) 2011-04-21
ES2359517T3 (es) 2011-05-24
US20090005406A1 (en) 2009-01-01
WO2007064753A2 (en) 2007-06-07
CY1111390T1 (el) 2015-08-05
PL1954281T3 (pl) 2011-07-29
DK1954281T3 (da) 2011-05-16
WO2007064753A3 (en) 2007-11-29
JP2009517397A (ja) 2009-04-30
EP2380572A1 (de) 2011-10-26
EP1954281B1 (de) 2011-03-09
EP1954281A2 (de) 2008-08-13
SI1954281T1 (sl) 2011-06-30
HRP20110244T1 (hr) 2011-04-30

Similar Documents

Publication Publication Date Title
ATE500831T1 (de) Krebsbehandlungsverfahren
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
EA200801168A1 (ru) Способ лечения
NO2010020I1 (no) 5-{{4-[(2,3-dimetyl-2H-indazot-6-yl)(metyl)amino]pyrimidin-2-yl}amino)-2-metylbenzensulfonamid Pazopanib.
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
CL2007001749A1 (es) Compuesto derivado de 2-arilamino-4-(heterociclo)aminopirimidina, inhibidores de la proteina quinasa c-alfa; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes, cancer, enfermedad cardiaca coronaria, aterosclerosis, entre otras.
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
WO2007143483A3 (en) Combination of pazopanib and lapatinib for treating cancer
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
DK1926729T3 (da) Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
EA200900034A1 (ru) Применение ингибитора р38 киназы для лечения психиатрических расстройств
ECSP077845A (es) Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas
MX2007013306A (es) Nuevas tiazolidinonas sin nitrogeno basico, su produccion y su uso como agentes farmaceuticos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1954281

Country of ref document: EP